Estradiol News and Research RSS Feed - Estradiol News and Research

Estradiol is a sex hormone. Mislabelled the "female" hormone, it is also present in males; it represents the major estrogen in humans. Estradiol has not only a critical impact on reproductive and sexual functioning, but also affects other organs including the bones.
Measuring levels of sex hormones in patients' blood may identify risk of sudden cardiac arrest

Measuring levels of sex hormones in patients' blood may identify risk of sudden cardiac arrest

Measuring the levels of sex hormones in patients' blood may identify patients likely to suffer a sudden cardiac arrest, a heart rhythm disorder that is fatal in 95 percent of patients. [More]
Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris Inc. today announced a strategic co-promotion services agreement with ASCEND Therapeutics US, LLC. [More]
Research suggests effective role for natural steroid hormones in treating breast cancer

Research suggests effective role for natural steroid hormones in treating breast cancer

A new study supports a growing body of research suggesting a safe and effective role for natural steroid hormones in treating postmenopausal breast cancer, with fewer detrimental side effects and improved health profile than with standard anti-hormone therapies. [More]
Researchers explore brain estrogens to mitigate learning and memory problems

Researchers explore brain estrogens to mitigate learning and memory problems

New studies being launched by neurobiologist Luke Remage-Healey at the University of Massachusetts Amherst will investigate how estrogens produced in the brains of young birds enhance their ability to learn songs during a critical window during development. [More]
Genentech agrees to acquire Seragon Pharmaceuticals

Genentech agrees to acquire Seragon Pharmaceuticals

Genentech, a member of the Roche Group, today announced it has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California. [More]
Conventional fertility hormones do not increase risk of breast, gynecological cancers

Conventional fertility hormones do not increase risk of breast, gynecological cancers

There is "little evidence" that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a substantial 30-year follow-up study. [More]
Menopause-related changes in sex hormones linked to greater risk for heart disease

Menopause-related changes in sex hormones linked to greater risk for heart disease

As hormone levels change during the transition to menopause, the quality of a woman's cholesterol carriers degrades, leaving her at greater risk for heart disease, researchers at the University of Pittsburgh Graduate School of Public Health discovered. [More]
Low levels of testosterone decline physical function in elderly men

Low levels of testosterone decline physical function in elderly men

Elderly men with low levels of testosterone or other sex hormones have twice the likelihood of having declining physical function over two years' time compared with their peers who have the highest hormone levels, a new study from Australia finds. [More]
Telephone-based weight loss intervention is effective in breast cancer treatments

Telephone-based weight loss intervention is effective in breast cancer treatments

A series of simple telephone calls can make a profound difference in helping women to meet their treatment goals for breast cancer, according to a randomized trial of women who are also obese, published online today in Journal of Clinical Oncology by Dr. Pamela Goodwin of Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research Institute. [More]
Childhood oestrogen may normalise thelarche in Turner syndrome

Childhood oestrogen may normalise thelarche in Turner syndrome

Treating girls with Turner syndrome with low-dose oestrogen from childhood results in earlier thelarche and a slower tempo of puberty, research shows. [More]
Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women. [More]
Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2014. [More]
Studies demonstrate new approaches to treating and preventing Parkinson's disease

Studies demonstrate new approaches to treating and preventing Parkinson's disease

A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease. [More]
Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013. [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013. [More]
More than 1/3 of women experience hot flashes for 10 years after menopause

More than 1/3 of women experience hot flashes for 10 years after menopause

A team of researchers from the Perelman School of Medicine at the University of Pennsylvania has found that moderate to severe hot flashes continue, on average, for nearly five years after menopause, and more than a third of women experience moderate/severe hot flashes for 10 years or more after menopause. [More]
Study points to gender-specific mechanisms of brain repair following oxygen deprivation

Study points to gender-specific mechanisms of brain repair following oxygen deprivation

Physicians have long known that oxygen deprivation to the brain around the time of birth causes worse damage in boys than girls. Now a study by researchers from the Johns Hopkins Children’s Center conducted in mice reveals one possible reason behind this gender disparity and points to gender-specific mechanisms of brain repair following such injury. [More]
OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Oasis Diagnostics Corporation is the recipient of a research award from The Michael J. Fox Foundation for Parkinson's Research to validate OASIS' development of a non-invasive, saliva-based, rapid test for Parkinson's disease detection and diagnosis. [More]
Actavis' subsidiary files ANDA for generic version of NuvaRing

Actavis' subsidiary files ANDA for generic version of NuvaRing

Actavis plc today confirmed that its subsidiary, Warner Chilcott Company LLC, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Ethinyl Estradiol and Etonogestrel Vaginal Ring, 0.015 mg/24 hour and 0.12 mg/24 hour. [More]